Ju‐Hee Bang

544 total citations
39 papers, 385 citations indexed

About

Ju‐Hee Bang is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Ju‐Hee Bang has authored 39 papers receiving a total of 385 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Molecular Biology and 13 papers in Surgery. Recurrent topics in Ju‐Hee Bang's work include Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers), PARP inhibition in cancer therapy (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Ju‐Hee Bang is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers), PARP inhibition in cancer therapy (8 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Ju‐Hee Bang collaborates with scholars based in South Korea, United States and Thailand. Ju‐Hee Bang's co-authors include Do‐Youn Oh, Kyung-Hun Lee, Yung‐Jue Bang, Tae‐Yong Kim, Tae‐You Kim, Seock‐Ah Im, Sae‐Won Han, Hyerim Ha, Ji‐Eun Park and Ji Eun Park and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Ju‐Hee Bang

36 papers receiving 381 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ju‐Hee Bang South Korea 11 261 158 83 79 60 39 385
Mohammed Shaik United States 8 139 0.5× 65 0.4× 54 0.7× 56 0.7× 188 3.1× 20 393
Jindřich Kopecký Czechia 13 227 0.9× 89 0.6× 168 2.0× 106 1.3× 16 0.3× 57 474
Yi‐Fang Chang Taiwan 12 153 0.6× 42 0.3× 65 0.8× 136 1.7× 84 1.4× 33 402
Byung Woog Kang South Korea 10 241 0.9× 79 0.5× 193 2.3× 66 0.8× 38 0.6× 21 406
Hari A. Deshpande United States 10 136 0.5× 57 0.4× 90 1.1× 120 1.5× 32 0.5× 46 363
Akito Dobashi Japan 9 188 0.7× 66 0.4× 62 0.7× 83 1.1× 20 0.3× 18 384
Lokanatha Dasappa India 9 106 0.4× 34 0.2× 40 0.5× 36 0.5× 44 0.7× 41 257
Kelly K. Curtis United States 12 130 0.5× 110 0.7× 146 1.8× 107 1.4× 10 0.2× 25 375
Laetitia Coutte France 5 268 1.0× 23 0.1× 53 0.6× 64 0.8× 46 0.8× 10 386
Smitha Menon United States 11 300 1.1× 29 0.2× 128 1.5× 134 1.7× 50 0.8× 18 474

Countries citing papers authored by Ju‐Hee Bang

Since Specialization
Citations

This map shows the geographic impact of Ju‐Hee Bang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ju‐Hee Bang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ju‐Hee Bang more than expected).

Fields of papers citing papers by Ju‐Hee Bang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ju‐Hee Bang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ju‐Hee Bang. The network helps show where Ju‐Hee Bang may publish in the future.

Co-authorship network of co-authors of Ju‐Hee Bang

This figure shows the co-authorship network connecting the top 25 collaborators of Ju‐Hee Bang. A scholar is included among the top collaborators of Ju‐Hee Bang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ju‐Hee Bang. Ju‐Hee Bang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Lee, Su In, Jae‐Min Kim, Ju‐Hee Bang, et al.. (2025). Therapeutic potential of BOLD-100, a GRP78 inhibitor, enhanced by ATR inhibition in pancreatic ductal adenocarcinoma. Cell Communication and Signaling. 23(1). 281–281. 2 indexed citations
4.
Bang, Ju‐Hee, et al.. (2024). Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells. Cell Communication and Signaling. 22(1). 518–518. 7 indexed citations
5.
Lee, Su In, Jae‐Min Kim, Ju‐Hee Bang, et al.. (2024). Abstract 380: Co-downregulation of GRP78 and ATR enhances apoptosis in pancreatic ductal adenocarcinoma. Cancer Research. 84(6_Supplement). 380–380. 1 indexed citations
6.
Bang, Ju‐Hee, et al.. (2022). A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers. Oncogene. 41(32). 3939–3952. 12 indexed citations
7.
Bang, Ju‐Hee, et al.. (2021). Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer. Cancer Research and Treatment. 54(2). 541–553. 10 indexed citations
8.
9.
Kim, Jin Won, Ji‐Won Kim, Tae-Yong Kim, et al.. (2021). DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.. Journal of Clinical Oncology. 39(15_suppl). TPS4166–TPS4166. 4 indexed citations
10.
Jin, Meihua, et al.. (2020). Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer. Cancer Research and Treatment. 52(3). 945–956. 19 indexed citations
11.
Park, Woo Chan, et al.. (2019). Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric cancer patients.. Journal of Clinical Oncology. 37(15_suppl). 4034–4034. 3 indexed citations
12.
Park, Hyunkyung, et al.. (2018). The role of soluble TGF-beta and its dynamics for predicting the prognosis in unresectable pancreatic cancer patients treated with chemotherapy.. Journal of Clinical Oncology. 36(4_suppl). 288–288. 1 indexed citations
13.
14.
Ock, Chan‐Young, Ju‐Hee Bang, Tae-Yong Kim, et al.. (2015). The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer.. PubMed Central. 5(11). 3376–88. 13 indexed citations
15.
Park, Ji Eun, Ju‐Hee Bang, Ling Jin, et al.. (2015). Abstract 1714: The role and mechanism of JAB1 as a therapeutic target in biliary tract cancer. Cancer Research. 75(15_Supplement). 1714–1714. 1 indexed citations
16.
Choi, Soo-Young, Sung‐Eun Lee, Soo-Hyun Kim, et al.. (2012). Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib: Updated Data From RE-Nice Study. Blood. 120(21). 3775–3775. 2 indexed citations
17.
Lee, Sung‐Eun, Soo Young Choi, Ju‐Hee Bang, et al.. (2012). The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate. Cancer Genetics. 205(11). 563–571. 17 indexed citations
18.
19.
Goh, Hyun‐Gyung, Soo-Young Choi, Ju‐Hee Bang, et al.. (2011). Discontinuation of Imatinib Therapy in Chronic Myeloid Leukemia Patients with Sustained Complete Molecular Response4.5 (CMR4.5). Blood. 118(21). 2763–2763. 6 indexed citations
20.
Goh, Hyun‐Gyung, Saengsuree Jootar, Hyeoung‐Joon Kim, et al.. (2011). Efficacy of Nilotinib Versus High-Dose Imatinib in Early Chronic Phase CML Patients Who Have Suboptimal Molecular Responses to Standard-Dose Imatinib (RE-NICE Multicenter Study). Blood. 118(21). 2765–2765. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mohammed Shaik Breakdown of academic impact, for papers by Jindřich Kopecký Breakdown of academic impact, for papers by Yi‐Fang Chang Breakdown of academic impact, for papers by Byung Woog Kang Breakdown of academic impact, for papers by Hari A. Deshpande Breakdown of academic impact, for papers by Akito Dobashi Breakdown of academic impact, for papers by Lokanatha Dasappa Breakdown of academic impact, for papers by Kelly K. Curtis Breakdown of academic impact, for papers by Laetitia Coutte Breakdown of academic impact, for papers by Smitha Menon
Rankless by CCL
2026